---

Transaction Summary

• Completed a $100M IPO in 2014
• Lead product, abicipar, started pivotal Phase III clinical trials for AMD - leading cause of blindness

• Zurich-Schlieren, Switzerland
• SIX: MOLN


• Contact:
  Petri Vainio
  
• IPO

Related News

• Molecular Partners Received a European Small and Mid-Cap Award
• Molecular Partners Secures CHF 46 million in Series B Financing Led by Essex Woodlands
• Molecular Partners Wins European Biotechnica Award 2015
• Bill Burns Nominated for Election to Molecular Partners’ Board of Directors